IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in its Alzheimer’s Pipeline November 14, 2024 Read More »
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies November 6, 2024 Read More »
IGC Pharma Announces Patient Enrollment at Toronto’s Baycrest in Phase 2 Trial Investigating IGC-AD1 October 17, 2024 Read More »